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Background: Depersonalization disorder (DPD) includes changes in subjective experiencing of self,
encompassing emotional numbing. Functional magnetic resonance imaging (fMRI) has pointed to
ventrolateral prefrontal cortex (VLPFC) inhibition of insula as a neurocognitive correlate of the disorder.
Objective: We hypothesized that inhibition to right VLPFC using repetitive transcranial magnetic stim-
ulation (rTMS) would lead to increased arousal and reduced symptoms.
Methods: Patients with medication-resistant DSM-IV DPD (N ¼ 17) and controls (N ¼ 20) were ran-
domized to receive one session of right-sided rTMS to VLPFC or temporo-parietal junction (TPJ). 1Hz
rTMS was guided using neuronavigation and delivered for 15 min. Co-primary outcomes were: (a)
maximum skin conductance capacity, and (b) reduction in depersonalization symptoms (Cambridge
Depersonalisation Scale (CDS) [state version]). Secondary outcomes included spontaneous ﬂuctuations
(SFs) and event-related skin conductance responses.
Results: In patients with DPD, rTMS to VLPFC led to increased electrodermal capacity, namely maximum
skin conductance deﬂections. Patients but not controls also showed increased SFs post rTMS. Patients
who had either VLPFC or TPJ rTMS showed a similar signiﬁcant reduction in symptoms. Event-related
electrodermal activity did not change.
Conclusions: A single session of right-sided rTMS to VLPFC (but not TPJ) signiﬁcantly increased physio-
logical arousal capacity supporting our model regarding the relevance of increased VLPFC activity to
emotional numbing in DPD. rTMS to both sites led to reduced depersonalization scores but since this was
independent of physiological arousal, this may be a non-speciﬁc effect. TMS is a potential therapeutic
option for DPD; modulation of VLPFC, if replicated, is a plausible mechanism.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Depersonalization disorder (DPD) is a psychiatric syndrome
characterized by persistent and distressing feelings of unreality and
alterations in a person’s sense of self [1] as deﬁned in DSM-IV-TRch Council. Emma-Louise Jay
for Health Research (NIHR)
stitute of Psychiatry, King’s
oundation Trust. We are also
mily Trusts.
d).
Inc. Open access under CC BY-NC-ND[2]. It is found in many cultures [3] and the condition affects
around 1% of the population [4]. It often begins in adolescence and
has a tendency for chronicity [5,6]. Depersonalization is frequently
a transient phenomenon in states of fatigue or fear [7] and can
appear as a symptom of other psychiatric disorders including panic
disorder [8]. Secondary forms are also well described in patients
with neurological conditions, such as temporal lobe epilepsy [9]
and following substance misuse [10,11]. A variety of pharmacolog-
ical treatments have been tried [12] but most fail to show sub-
stantial beneﬁts [13]. A cognitive behavioral model has been
developed [14] but has not been subjected to a randomized
controlled trial [15].
A neurobiological model of DPD has also been proposed [16],
hypothesizing dysfunctionally increased fronto-insula/limbic
inhibitory regulation. This model is consistent with neurological
case studies [17] and has been reﬁned by neuroimaging research
using fMRI [18,19], which has demonstrated reduced insula, limbic license.
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pictures, and increased VLPFC activation. Psychophysiological
studies using skin conductance response (SCR) measures [20] have
found reduced autonomic responses in patients with DPD to un-
pleasant, emotive stimuli, in comparison to those with anxiety
disorders and to healthy controls [21]. Work combining fMRI and
SCR has shown a correlation between dorsolateral and ventral
prefrontal and ‘limbic’ activation in response to emotional faces in
DPD [22,23] which is consistent with the functional (reciprocal)
interaction seen between VLPFC and insula in healthy volunteers
[24], and patients with anxiety states [25]. Finally, preliminarywork
[26] shows that reduced right VLPFC (and increased insula) acti-
vation on fMRI corresponds to symptomatic improvement in DPD
patients treatedwith lamotrigine [27]. This body of work appears to
point to a mechanism for the emotional numbing frequently
experienced by DPD suffers and may even relate to a core abnormal
experiencing of the sense of self [28].
Transcranial magnetic stimulation (TMS), a non-invasive brain
stimulation technique, is well established both as a research tool
and therapeutic intervention in a range of psychiatric disorder [29].
Of relevance to DPD, rTMS has been used to examine the role of the
prefrontal cortex in emotional regulation. A single session of rTMS
to the right DLPFC induced impairments in participants’ ability to
inhibit negative emotion processing in a facial evaluation task [30].
Other studies found that low frequency (inhibitory) rTMS to the
right DLPFC in healthy participants could induce risk-taking
behavior on a gambling paradigm [31] and reduce participants’
willingness to reject unfair offers on ‘the ultimatum game’ [32,33].
High frequency (excitatory) rTMS to the left DLPFC can reduce food
craving [34], cigarette smoking [35] and cocaine craving [36]
compared to sham TMS. These studies indicate that rTMS can
modulate behavior and motivational states by enhancing or atten-
uating inhibitory prefrontal mechanisms.
There have been two single case reports, and one trial reporting
the usage of TMS in DPD. The ﬁrst was a woman with co-morbid
DPD and major depression (MDD) [37] whose single photon
emission computed tomography (SPECT) scan showed right frontal
hyperactivity, which was the target of 1Hz rTMS. It was reported
that her self-awareness increased and depersonalization symptoms
decreased. In a second case study, a 24 year-oldmalewith comorbid
DPD and MDD who had not responded to pharmacotherapy also
received an SPECT scan [38]. The scan showed hypoperfusion
bi-temporally and in the left frontoparietal region. rTMS was
delivered to the left DLPFC, and a 28% reduction in symptoms was
reported after 6 sessions. Finally, a trial in twelve DPD patients
reported that half responded to temporal parietal junction (TPJ)
TMS after three weeks of treatment [39]. The TPJ regionwas chosenTable 1
Baseline characteristics of all participants, DPD patients and controls e separated accord
Patients with DPD (N ¼ 17)
VLPFC (N ¼ 8)
Age, mean (SD) 34.9 (5.2)
Gender 7 male
Taking psychotropic medication 3
Duration of DPD (years) 15.1 (9.7)
Age of DPD onset 16.7 (5.9)




Resting motor threshold 56.4 (4.5)
Baseline SCR (msiemens) 0.5 (0.8)
Baseline SCL (msiemens) 3.2 (1.6)
DPD, depersonalization disorder; VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-par
Beck Depression Inventory; SCR, skin conductance response; SCL, skin conductance levedue to its relevance in out of body experiences (OBEs), researched
previously using TMS [40,41]. Five out of the six responders showed
a 68% reduction in symptoms after a total of six weeks treatment.
Unfortunately, none of these studies utilized either sham or active
control conditions, so it is not possible to exclude placebo effects. In
addition there was no ofﬂine-testing of behavioral or physiological
markers.
The overall aims of this research were to ﬁrstly use low fre-
quency TMS stimulation to test a neurobiological model of DPD,
whereby the VLPFC was the target site of stimulation, the TPJ taking
the role as active control site of stimulation, and secondly compare
the potential therapeutic utility of these two sites of stimulation for
future controlled clinical trials in DPD. We chose VLPFC rather than
DLPFC because of the balance of evidence pointing to the former in
DPD reviewed above, and its role in regulation of abnormal states of
anxiety and arousal [25] despite the greater experience of TMS
delivered to the DLPFC, and the likelihood that DLPFC as well as
ventral and indeed medial frontal regions are also involved in
emotion modulation [42].
We sought to test the hypothesis that low frequency (inhibitory)
rTMS to the right VLPFC in patients with DPDwould cause increases
in autonomic arousal (SCRs) and decreases is symptoms of DPD.
Methods and materials
Ethical approval
NHS Research Ethics Review System, London, approved this
research in accordance with the declaration of Helsinki. All partic-
ipants gave written informed consent.
Participants
There were N ¼ 43 participants in total: 22 had a primary
diagnosis of DPD (DSM-IV TR) based on a detailed interview by the
clinic psychiatrist. Patients were recruited through the Deperson-
alization Unit Clinic, a specialist outpatients service based at the
Maudsley Hospital, South London. There were 21 healthy controls;
these were staff and students of King’s College London and local
residents who responded to adverts for volunteers.
Inclusion criteria for cases: a current primary diagnosis of DPD
and scores >70 on the Cambridge Depersonalization Scale [43]. All
were unresponsive to at least one medication, although the ma-
jority had failed to respond to several and had been ill for at least 2
years. Patients taking medications could participate in the trial if
their medication did not have safety contraindications with rTMS
[44] and if they had been on a stable dose for at least two weeks.ing to allocation to TMS condition.
Healthy controls (N ¼ 20)
TPJ (N ¼ 9) VLPFC (N ¼ 11) TPJ (N ¼ 9)
39.3 (14.6) 30.1 (4.4) 28.3 (7.0)
6 male 5 male 3 male
5 0 0
12.4 (16.7) e e
22.3 (15.3) e e
119.2 (33.7) 7.6 (9.6) 20.3 (21.8)
30.0 (14.2) 4.3 (2.0) 12.0 (12.3)
36.4 (14.0) 2.3 (1.9) 6.7 (9.4)
14.0 (7.9) 4.5 (3.5) 12.0 (10.1)
52.7 (2.8) 52.5 (6.2) 51.3 (2.2)
0.6 (0.5) 0.8 (0.9) 0.7 (0.4)
4.0 (2.3) 3.2 (2.0) 3.4 (1.4)
ietal junction; DES, Dissociative Experiences Scale; BAI, Beck Anxiety Inventory; BDI,
l.
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personal history of severe headaches, a current or historical
neurological diagnosis, a personal or family history of seizures or
epilepsy, anymedical condition involving a loss of consciousness, or
the violation of MRI safety contraindications including metal in the
body. Participants were screened using the CDS; controls were
excluded if they scored >70.
One patient did not attend her MRI scan due to anxiety and so
was not able to continue participation. A further ﬁve participants
(N ¼ 4 with DPD) were excluded from analyses; one patient’s MRI
scan revealed marked cortical atrophy of unknown cause; another
could not complete all measures due to technical equipment
problems and 3 were because of other protocol violations.
Assessments
Socio-demographic variables were recorded on all subjects. As
noted, all subjects completed the CDS, a self-assessment instrument
with good reliability and validity, which has state and trait versions.
A score of 70 (out of a possible maximum 290, trait version) has a
sensitivity of 75.5% and speciﬁcity of 87.2% as a clinical cut-off [43].
The CDS has a ‘state’ version (CDS-S) adapts 22 of the 29 items,
which lend themselves to a ‘here and now’ rating, and uses the
mean score expressed as a percentage. The scale has high reliability
and has been shown to be sensitive to symptom change [15]. Other
scales included the Beck Depression Inventory [45] and Beck Anx-
iety Inventory [46] and the Dissociative Experiences Scale [47]. All
subjects underwent a full psychiatric assessment and duration of
illness and treatment history was recorded (Table 1).
Participants were pseudorandomized to receive either VLPFC or
TPJ TMS stimulation with the constraint of ensuring approximately
equal numbers in each given the relatively small sample size. They
were blind to the study hypotheses and predicted effects of the two
stimulation sites. Researchers were not blind to site allocation.
Since TPJ could also be therapeutically beneﬁcial for patients but
through an unrelatedmechanism to that under investigation, it was
considered ideal from both an ethical and methodological point of
view as an active control [48].
Procedures
A structural MRI was obtained for all participants prior to TMS.
MRI data were acquired on a GE 1.5 T HDx system (General Electric,
Milwaukee, WI, USA) at the Institute of Psychiatry, London. Local-
izer and calibration scans were followed by 2D T2-weighted Fast
Spin Echo and FLAIR (Fluid Attenuated Inversion Recovery) scans. A
3D T1-weighted Inversion Recovery prepared Spoiled Gradient
Echo (IR-SPGR) scan was then collected with the following pa-
rameters: TE ¼ 5 ms; TR ¼ 12 ms; TI ¼ 300 ms; excitation ﬂip
Table 2
Maximum capacity for skin conductance response.
TIME POINT Depersonalization disorder (N ¼ 17)
VLPFC (N ¼ 8) TPJ (N ¼ 9) Total (N ¼ 1
Pre TMS 4.66 (2.93) 5.39 (2.82) 5.05 (2.81)
Post TMS 6.37 (4.37) 5.19 (3.03) 5.74 (3.65)
Statistical analysis
Main effects ANOVA Post-hoc Signiﬁcant interactions




Subject type F[1,33] ¼ 0.0; P ¼ 0.98 NS
DPD, depersonalization disorder; VLPFC, ventrolateral prefrontal cortex; TPJ, temporo
conductance response.angle ¼ 18; matrix size 320  224  220 over a 288  202  198
ﬁeld of view, giving an isotropic 0.9 mm voxel size over the whole
brain. Images were converted to DICOM format for use within
BrainSight-v2 neuronavigation software program. Neuronavigation
has been demonstrated to improve the accuracy of positioning a
TMS coil [49]. BrainSight ensures that TMS stimulation can only be
delivered when the target site is positioned using the frameless
stereotaxy.
Skin conductance
Two silver-chloride electrodes 0.5 cm in diameter were attached
to the participants’ non-dominant hand at the distal phalanges as
per previous research [21]. The SC4 module (Contact Precision In-
struments) was used to record skin conductance, attached to a
laptop, recording SC signals at 100 mS intervals. Water-soluble
electrolyte jelly was used as an electrolyte as per recommended
guidelines [50]. These readings were synchronized with a picture
presentation.
Stimulus presentation
An initial set of pictures was shown from the International Af-
fective Picture System (IAPS) [51] in color on a laptop 1 m from the
participant prior to rTMS and then the other set, again following
rTMS. The two sets, A or B were matched for normative ratings of
valence and arousal; participantswere randomized to receive either
set A or set B of the picturesﬁrst. After being asked to sit comfortably
for 1min, and then take a deep sigh (which reliably produces a large
SCR), sixteen neutral, non-arousing pictures admixed with and
sixteen aversive, emotionally-arousing pictures were shown. Each
picture was shown for 2 s, after which the self-assessment manikin
(SAM) [52] was shown for 13 s. The SAMuses a cartoon-like dummy,
which depicts different states from 1 (feel most aroused) to 9 (feel
nothing). Participants were requested to look at the picture, and
when the SAM appeared to call out verbally the number on the scale
which best ﬁtted “how emotionally provoked [they] felt by the
picture.” SCRswere recordingwhilst participants looked at the SAM;
this period included a 1e4 s post-IAPS image window for event-
related SCRs with the remainder allowing recording of sponta-
neous ﬂuctuations (please see below).
rTMS
Resting motor threshold (MT) in M1, deﬁned as the lowest in-
tensity of TMS which yielded motor-evoked potentials (MEPs) of at
least 50 mV in 5 out of 10 trials using an MEP pod, was determined
from electromyographic (EMG) activity in the abductor pollicis
brevis using surface electrodes. Co-registration of the participantHealthy controls (N ¼ 20)
7) VLPFC (N ¼ 11) TPJ (N ¼ 9) Total (N ¼ 20)
4.89 (3.33) 4.58 (2.10) 4.75 (2.78)
4.97 (3.80) 7.05 (3.99) 5.91 (3.93)
; P < 0.01 DPD patients who receive VLPFC rTMS show increases in Max. SCR
post rTMS
t ¼ 2.15, df ¼ 7, P < 0.05
Controls who receive TPJ rTMS show increases in Max. SCR post rTMS
t ¼ 2.14, df ¼ 8, P ¼ 0.05
-parietal junction; rTMS, repetitive transcranial magnetic stimulation; SCR, skin
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Montreal) [53], and coil calibration were performed. ‘Target sites’
for stimulation using the Simple Point method were set prior to the
participant’s arrival by entering their Talairach coordinates as per
their group allocation. The VLPFC coordinates (Right VLPFC x ¼ 35,
y ¼ 25, z¼ 7) were selected to correspond to Brodmann Area (BA)
47 which was found to be active in only patients with a diagnosis of
DPD in response to aversive scenes in an fMRI task [18]. The TPJ
coordinates (Right TPJ x ¼ 63, y ¼ 37, z ¼ 20) were selected as per
previous research using neuronavigation, which studied OBEs and
self-processing [40] and TMS stimulation of the right TPJ [41]. The
coil was held tangential to the scalp of the head with the handle
pointing back away from midline at 45. Participants then received
15min rTMS delivered at 1Hz and 110%MT to either the right VLPFC
or right TPJ, as per their group allocation using a Magstim
RMA6802, 3014-00 Rapid2 Dual PSU ﬁgure-of-eight coil (Magstim
Co. Ltd., UK) e i.e. 900 pulses. Following TMS, outcome measures
were completed plus a side-effects checklist, and all participants
were debriefed and offered a nominal cash sum for their time and
expenses. Finally a semi-structured telephone interview was con-
ducted 24 h later.
Main outcome measures
In this study, the minimum amplitude of SCRs and SFs measured
was 0.04 mS. We recorded three types of electrodermal measure for
analysis:
(1) Maximum amplitude of skin conductance deﬂections; tradition-
ally used as a key index of individual differences in capacity to
generate autonomic activity [50], it measures the highest single
deﬂection in skin conductance recorded across all epochs. We
reasoned that increased arousal capacity is likely to coincide
with increased reactivity in DPD. We deﬁned the maximum
skin conductance as the highest recorded amplitude during any
15 s epoch, during or after stimulus presentation.
(2) Spontaneous ﬂuctuations (SFs); the number of skin conductance
deﬂections in the absence of an identiﬁable eliciting stimuluse
a general measure of autonomic reactivity [50]. SFs were
recorded following each 2 s picture presentation and outside
the 1e4 s event-related window (i.e. the ﬁrst 1 s and last 9 s of
each 15 s epoch).Figure 1. (A, B) Maximum skin conductance deﬂection of depersonalization disorder patien
ventrolateral prefrontal cortex; TPJ, temporo-parietal junction; rTMS, repetitive transcrania(3) Event-related SCRs; electrodermal responses to an identiﬁable
stimulus, including phasic increase in deﬂection amplitude and
changes in latency of response from stimulus onset. The time
window was deﬁned as a latency of between 1 and 4 s
following the 2 s IAPS picture presentation.
In addition, depersonalization symptoms were measured using
the self-report state version of the CDS immediately after TMS. A
symptom reduction of at least 25% was considered clinically sig-
niﬁcant and “responsive” to TMS as per previous research [39]. All
outcome measures were recorded pre and post rTMS for
comparison.
Statistical analyses
SPSS version 20 was used for statistical analyses. Analysis of
variance (ANOVA) was used to compare post rTMS session outcome
measures between those allocated to either VLPFC or TPJ stimula-
tion groups, and in patients and controls. A series of 2 2 2mixed
model repeated measures ANOVAs was performed for each of the
dependent variables: with a within subjects factor: rTMS (pre- and
post); and two between groups factors, ‘participant group’: ‘DPD
patients’ or ‘healthy controls’ and ‘site of stimulation’: ‘VLPFC’ or
‘TPJ.’ Covariates of BDI, BAI and DES were not used because their
variance was not equal across the independent variable [54] but
were entered into a multiple regression as potential predictors of
outcome. Paired or student’s t-tests were used to explore
interactions.
Results
Baseline characteristics of all participants are summarized in
Table 1. There were no signiﬁcant differences between participants
randomized to either VLPFC or TPJ stimulation. Inspection does
show that the DPD group was somewhat older and contained fewer
females.
Measures of electrodermal activity
In terms of maximum capacity for SC, there was a main effect of
rTMS (F[1,33]¼ 7.3; P¼ 0.01). Maximum SCRs were generally larger
post rTMS. However, there was a signiﬁcant interaction betweents and healthy controls for both VLPFC and TPJ rTMS. DPD patients and controls. VLPFC,
l magnetic stimulation; SE, standard error.
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[1,33] ¼ 8.2; P < 0.01). Post hoc t-tests showed that patients with
DPD who received VLPFC rTMS increased their maximum SCR post
rTMS (t ¼ 2.2, df ¼ 7, P < 0.05) with controls showing no signif-
icant change (Table 2). TPJ rTMS given to DPD patients did not
produce any appreciable change while, curiously, it did increase
maximum SCR in controls (t ¼ 2.1, df ¼ 8, P ¼ 0.05) (see Fig. 1A
and B).
In terms of the number of SFs, there were no signiﬁcant main
effects. There was a signiﬁcant interaction between effect of rTMS
and participant group (F[1,33] ¼ 7.3; P ¼ 0.01; see Table 3; Fig. 2).
From the ﬁgure it appears that the interaction reﬂects the patients’
tendency to show an increase in SFs post rTMS (Paired t-tests:
t ¼ 1.83, df ¼ 16, P ¼ 0.08), while controls show a decrease
(t ¼ 2.11, df ¼ 19, P ¼ 0.048).
There was also a suggestion that the 2 sites of TMS may differ
although the 3-way interaction between TMS, group and site was
not signiﬁcant. Nevertheless given our a priori interest in the effect
of VLPFC on autonomic function in DPD we carried out paired t-
tests which showed a trend increase in patients’ SFs following
VLPFC (t ¼ 2.11, df ¼ 7, P ¼ 0.07) which was much weaker
following TPJ stimulation (P ¼ 0.4). In sum, rTMS appeared to in-
crease SFs in patients rather than controls and there was a sug-
gestion that this effect was stronger following VLPFC stimulation
(see Fig. 2).
There were no signiﬁcant differences post rTMS in event-related
responses for cases and controls for measures including latency,
and ‘amplitude’ uncorrected and corrected for electrodermal
capability (maximum SC).
Subjective rating of depersonalization
As expected, there was a main effect of participant group (F
[1,33] ¼ 100.3; P < 0.01) with DPD patients scoring higher on the
CDS-S than healthy controls: pre-TMS DPD (mean (SD) 42.0 (15.6)
vs. controls mean 1.8 (2.7)). There was a main effect of rTMS (F
[1,33] ¼ 21.1; P < 0.01) but no effect of site of stimulation (F
[1,33] ¼ 0.1; P ¼ 0.70). There was an interaction between the effect
of rTMS and participant group (F[1,33] ¼ 28.7; P < 0.01; Table 1;
Fig. 3). Post hoc t tests (t¼ 4.8, df¼ 16, P< 0.01) found that patients
with DPD showed a signiﬁcant decrease in depersonalization
symptoms post VLPFC rTMS (CDS-S score 31.3 (14.9)) and TPJ rTMS
(CDS-S score 32.1 (17.6)), whereas healthy controls, marginally
increased their depersonalization scores post VLPFC rTMS and TPJ
rTMS (t ¼ 2.2, df ¼ 19, P ¼ 0.04) (see Fig. 3A and B).
Adverse effects
All TMS participants completed the full session and no one chose
to discontinue. One experienced a mild headache and another mildTable 3
Spontaneous ﬂuctuations (SFs) in skin conductance.
Time point Depersonalization disorder (N ¼ 17)
VLPFC (N ¼ 8) TPJ (N ¼ 9) Total (N ¼ 1
Pre TMS 2.45 (1.62) 2.20 (1.64) 2.32 (1.58)
Post TMS 3.08 (1.20) 2.59 (1.59) 2.82 (1.40)
Statistical analysis
Main effects ANOVA Post-hoc Signiﬁcant interactions
rTMS NS NS rTMS*
Group
F[1,33] ¼ 7.27; P ¼ 0.01 DPD patients after V
t ¼ 2.11, df ¼ 7, PGroup NS NS
DPD, depersonalization disorder; VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-pa
ﬂuctuations; SCR, skin conductance response.difﬁculties concentrating after rTMS. Three participants experi-
enced “twitching or jerking” sensations and one felt “more pre-
sent,” experiences conﬁned to right VLPFC stimulation. Two
experienced ‘drunk-like’ feelings after right TPJ stimulation.
Multiple regression
All participants were included in the modeling since scales
covered dimensions of psychopathology spanning healthy controls
and DPD patient scores. Dependent variables were: maximum SC,
SFs and CDS-S scores. Independent variables entered stepwise
were: the CDS-Trait score, DES, BDI and BAI scores; gender and age.
The results showed that none of the variables inﬂuenced maximum
SC or SFs in response to rTMS. For the post rTMS CDS-S measure,
baseline CDS, DES and BAI scores each contributed signiﬁcantly to a
total variance of 79% with b coefﬁcients of 0.65, 0.46 and 0.22,
respectively.
Discussion
The ﬁndings support our hypothesis that rTMS to the VLPFC
increases autonomic activity in DPD patients. We found that pa-
tients with DPD produce a signiﬁcant increase in the size of their
maximum skin conductance response after rTMS but only in the
VLPFC condition. Conversely, healthy controls show a different
pattern of response, and only increase in their maximum SCRs after
TPJ stimulation. We chose to record and analyze maximum SC
deﬂection because it gives a measure of a person’s capacity to
respond autonomically to external or interoceptive stimuli, which
has been found attenuated in DPD.
This ﬁnding in patients with DPD is suggestive of a disinhibitory
effect of right VLPFC rTMS. Previous neuroimaging studies have
shown hyperactivation in prefrontal areas in patients with DPD
[18,22,23]. Such frontal activation is functionally related to lack of
activation in emotion-generation related areas, e.g. the anterior
insula [24], and increased frontal activity has been found to be
inversely correlated with skin conductance responses [18].
It is not clear why healthy controls show a similar increase on
maximum SCRs after TPJ stimulation. A previous study using low
frequency rTMS on the right TPJ found a disruptive effect on the
subjective sense of embodiment and the distinction between self
and not-self, suggesting that the TPJ is actively involved in main-
taining a coherent sense of one’s body distinct from external non-
corporeal objects [55].
Spontaneous SC ﬂuctuations (SFs) are considered an overall in-
dex of skin conductance reactivity and it has been reported that
patients with DPD who go into remission show an increase in SFs
[20], akin to the tracings of anxiety patients. Post rTMS there was an
increase in patients’ SFs regardless of site while healthy controls
tended to show fewer SFs, again, regardless of site. This might beHealthy controls (N ¼ 20)
7) VLPFC (N ¼ 11) TPJ (N ¼ 9) Total (N ¼ 20)
2.65 (1.16) 3.28 (1.41) 2.93 (1.28)
2.16 (1.02) 2.94 (1.56) 2.51 (1.31)
LPFC show trend to increase SFs post rTMS: (paired t-test)
¼ 0.07; and after TPJ show no increase SFs post rTMS: t ¼ 0.85, df ¼ 8, P ¼ 0.42
rietal junction; rTMS, repetitive transcranial magnetic stimulation; SFs, spontaneous
Figure 2. Spontaneous ﬂuctuations (SFs) in skin conductance for both depersonal-
ization disorder patients (DP) and healthy controls (C) receiving either VLPFC or TPJ
TMS (transcranial magnetic stimulation). VLPFC, ventrolateral prefrontal cortex; TPJ,
temporo-parietal junction.
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rTMS, which could be beneﬁcial in DPD patients although a modest
trend was observed following post-hoc testing for a greater in-
crease following VLPFC rTMS given to DPD patients, in line with our
speciﬁc predictions.
We measured different parameters of skin conductance during
each of the 15-s epochs inside the 1e4 s event-related window for
IAPS pictures pre and post rTMS. No signiﬁcant results were found
for amplitude or for latency of SCR. One reason for the lack of
change with event-related SCRs could be due to the problem of
habituation to the emotional pictures contained in the IAPS e even
though non-identical images were shown pre and post TMS. Few
studies have explored the effect of prefrontal TMS on SCRs in
general, but one study found that anterior frontal 1Hz rTMS
reduced SCRs [56].
Our other main outcome measure was intensity of depersonal-
ization symptoms on the CDS-State version pre and post rTMS. It
was found that patients decreased in their scores post rTMS. Con-
trols slightly increased in their scores but they were still way below
clinical levels. These ﬁndings were irrespective of site of stimula-
tion. The mean reduction in CDS-S scores was 28.8% (27.3 (17.5) andFigure 3. (A, B) Scores on the Cambridge Depersonalization Scale state version pre and post
TPJ, temporo-parietal junction.30.1 (23.3) for VLPFC and TPJ, respectively, P ¼ 0.79) and is note-
worthy following just a single session of rTMS. Five of eight patients
with DPD receiving a single session of right VLPFC stimulation
wouldmeet criteria for being a ‘partial responder’ i.e. showed a 25%
reduction in CDS scores post rTMS. In the TPJ condition, results
were similar; out of N ¼ 9 patients with DPD, N ¼ 4 would meet
criteria for being a partial responder, and N ¼ 1 would be classed as
a full responder i.e. showed a 50% reduction in CDS scores post
rTMS, according to criteria [39].
In the earliest trial [37], a patient was treated with 1Hz rTMS to
the right prefrontal cortex. The next day, she reported dramatic
improvement. Although her progress reportedly did not continue in
the coming weeks, this is further evidence that after only 1 session
signiﬁcant improvements may be achieved. Another early trial [38],
reported a patient with continuous DPD for seven years. Interest-
ingly, 24 h after DLPFC rTMS, a 15% reduction in visual-analogue
scales of DPD was reported. After six sessions, a 28% reduction in
CDS scores was reported. In the case series [39], patients reported a
35% reduction in symptoms after receiving 3 weeks right-sided TPJ.
These results indicate that, based purely in terms of reduction on
CDS-S scores alone, both VLPFC and TPJ stimulation may be bene-
ﬁcial to patients, working via different neurobiological mechanisms
relevant to DPD. Patients with DPD sometimes complain of the
feeling that their self and body are somehow disconnected and this
is akin to feelings of disembodiment, which are provoked by
physiological disruption to the TPJ [40,41] and hence could
conceivably be ameliorated by rTMS. A recent secondary analysis
[57] found that in those patients who beneﬁtted from TPJ stimu-
lation, symptoms of anomalous body experience, as rated from the
CDS improved particularly, although emotional numbing also
improved. Indeed we found that scores on the CDS state scale item
that loads most heavily on emotional numbing (“I am not feeling
any emotions at all”), fell following VLPFC but not TPJ stimulation.
On the other hand, the item: “. I feel automatic andmechanical, as
if I were a robot,” fell somewhat more following TPJ stimulation
than VLPFC.
Another possibility is that rTMS in both VLPFC and TPJ can affect
autonomic arousal e directly or indirectly e as indexed by spon-
taneous ﬂuctuations in electrodermal activity. Interestingly, ventral
frontal cortex and TPJ are implicated in network which appears to
be specialized in directing attention to salient stimuli [58], and this
may even extend to social cognitive functions [59] which may beVLPFC and TPJ rTMS. DPD patients and controls. VLPFC, ventrolateral prefrontal cortex;
E.-L. Jay et al. / Brain Stimulation 7 (2014) 252e259258disrupted in DPD. This might explain who TMS to the 2 sites may
produce convergent effects. Subjective improvements such as
symptom severity are susceptible to placebo effects. Patients may
have high expectations of the treatment, which did not contain a
sham condition. Improvement in CDS-S scores was inﬂuenced by
baseline severity of depersonalization symptoms as well as broader
anxiety and dissociative symptoms e according to the multiple
regression analysis e which could be interpreted as regression to
the mean. Nevertheless, it should be noted DPD are notoriously
resistant to placebo effects in clinical trials [60].
We were concerned that VLPFC stimulationwith rTMS would be
poorly tolerated because of the inevitable muscular contraction
around the eye. However, pilot work and post-experimental
debrieﬁng did not reveal this to be a problem, at least not at the
frequencies used. Indeed therapeutic uses of VLPFC rTMS have been
reported, such as for tinnitus [61]. Similarly, our ﬁndings were
speciﬁc to right-sided stimulation e selected again based on pre-
vious empirical work but also to avoid potential disruption of lan-
guage and verbal memory which might follow left side stimulation.
Indeed both sites (VLPFC and TPJ) were in the right hemisphere
hencewe cannot comment onwhether left hemisphere stimulation
would have had the same therapeutic and physiological effects.
Differences found on key non-event related autonomic vari-
ables such as maximum SCRs by site of stimulation, indicates that
distinct physiological perturbations were produced by TMS in DPD
patients despite transynaptic effects which justiﬁes stereotaxy-
guided neuronavigation technology used to improve focality and
consistency.
We considered alternative prefrontal sites for TMS stimulation.
The DLPFC has been explored extensively in the clinical and non-
clinical cognitive neuroscience literature, in part because its
accessibility as well as its theoretical importance. As noted, the
evidence is stronger for the role of VLPFC in DPD, due, we hy-
pothesized, to its role in emotional control. Ventrolateral, orbito-
medial and dorsolateral prefrontal regions each play a role in
emotionecognition interactions [42,62]. DLPFC seems particularly
implicated in decision making which is emotionally biased, while
more ventral regions modulate (and may inhibit) emotional
response. Indeed source localization analyses of ERP data to an
emotional go/no-go task [63] revealed right VLPFC activation in
affective response inhibition whereas anterior cingulate activation
was sensitive to emotional valence but not inhibition. Furthermore,
low-frequency rTMS to the right DLPFC combined with H2O15
positron emission tomography revealed regional cerebral blood
ﬂow increases under the stimulation site as well as ipsilateral
ventrolateral PFC [64]. Similarly, rTMS to right DLPFC in conjunction
with an attention task produced changes detected using fMRI in
both ipsi- and contra-lateral VLPFC [65].
Limitations
Increasing the sample size would obviously be desirable to
improve statistical power and permit sub-group analyses, although
the current study is the ﬁrst ever caseecontrol comparison and
builds on previous case reports and series. Naturally, the healthy
controls were unlikely to be comparable with the cases in terms of
general psychopathology although when this was considered in the
multiple regression, it emerged that the effect of rTMS on the main
objective outcome measure, maximum SCR, was not inﬂuenced by
baseline psychopathology (although change in symptom scores
was).
Besides the modest sample size, the other major limitation was
the absence of a sham condition. Sham TMS is not however without
technical and methodological difﬁculties [66] although technolog-
ical advances have facilitated high quality controlled trials. Blindingis hard tomaintain and the use of active coils held at 90 to the skull
may in fact produce physiological effects. Future coils, which mimic
real rTMS sufﬁciently to blind the participant are likely to be
developed. In the absence of this, an alternative active control site
could be considered such as occipital cortex, although this can
interfere with visual stimuli and produce unwanted sensations.
Conclusion
A single session of right-sided 1Hz rTMS to VLPFC or TPJ stim-
ulation signiﬁcantly reduces depersonalization symptoms in pa-
tients. This procedures resulted in changes in non-event related
electrodermal responses namely increased maximum SCR (VLPFC
only) and increased SFs, whilst there was no change to event-
related responses. Changes in symptoms might reﬂect physiologi-
cally driven improvements in DPD but placebo effects cannot be
entirely excluded. These proof-of-concept ﬁndings, if replicated in a
larger sample, should inform a randomized controlled clinical trial
comparing multiples session rTMS at hypothesized therapeutic
sites of stimulation (either VLPFC or TPJ) using low frequency
neuronavigation-guided rTMS with sham stimulation.
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